Shareholders might have noticed that USANA Health Sciences, Inc. (NYSE:USNA) filed its quarterly result this time last week. The early response was not positive, with shares down 3.3% to US$13.86 in the past week. Revenues fell 5.3% short of expectations, at US$206m. Earnings correspondingly dipped, with USANA Health Sciences reporting a statutory loss of US$0.30 per share, whereas the analyst had previously modelled a profit in this period. This is an important time for investors, as they can track a company’s performance in its report, look at what expert is forecasting for next year, and see if there has been any change to expectations for the business. We’ve gathered the most recent statutory forecasts to see whether the analyst has changed their earnings models, following these results.
Taking into account the latest results, the current consensus from USANA Health Sciences’ one analyst is for revenues of US$945.0m in 2027. This would reflect a satisfactory 4.4% increase on its revenue over the past 12 months. USANA Health Sciences is also expected to turn profitable, with statutory earnings of US$1.29 per share. Yet prior to the latest earnings, the analyst had been anticipated revenues of US$945.0m and earnings per share (EPS) of US$1.29 in 2027. The consensus analyst doesn’t seem to have seen anything in these results that would have changed their view on the business, given there’s been no major change to their estimates.
See our latest analysis for USANA Health Sciences
The analyst reconfirmed their price target of US$25.00, showing that the business is executing well and in line with expectations.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. One thing stands out from these estimates, which is that USANA Health Sciences is forecast to grow faster in the future than it has in the past, with revenues expected to display 3.5% annualised growth until the end of 2027. If achieved, this would be a much better result than the 5.7% annual decline over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 4.4% per year. Although USANA Health Sciences’ revenues are expected to improve, it seems that the analyst is still bearish on the business, forecasting it to grow slower than the broader industry.
The Bottom Line
The most obvious conclusion is that there’s been no major change in the business’ prospects in recent times, with the analyst holding their earnings forecasts steady, in line with previous estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that said, the long-term trajectory of the company’s earnings is a lot more important than next year. We have analyst estimates for USANA Health Sciences going out as far as 2027, and you can see them free on our platform here.
You can also see our analysis of USANA Health Sciences’ Board and CEO remuneration and experience, and whether company insiders have been buying stock.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
